Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.

Senan, S; Özgüroğlu, MUSTAFA; Daniel, D; Villegas, A; Vicente, D; Murakami, S; Hui, R; Faivre-Finn, C; Paz-Ares, L; Wu, Y; Mann, H; Dennis, P; Antonia, S

doi:10.1016/j.esmoop.2022.100410

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.

Senan S., Özgüroğlu M., Daniel D., Villegas A., Vicente D., Murakami S., ...More

ESMO open, vol.7, no.2, pp.100410, 2022 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 7 Issue: 2
Publication Date: 2022
Doi Number: 10.1016/j.esmoop.2022.100410
Journal Name: ESMO open
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
Page Numbers: pp.100410
Keywords: immunotherapy, radiation therapy, chemotherapy, surgery, multimodality therapy, RANDOMIZED CONTROLLED-TRIAL, PHASE-III, PREOPERATIVE CHEMOTHERAPY, INDUCTION CHEMOTHERAPY, SURGICAL RESECTION, RADIOTHERAPY, N2, SURGERY
Open Archive Collection: AVESIS Open Access Collection
Istanbul University-Cerrahpasa Affiliated: No

Abstract

Background: The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression following chemoradiotherapy (CRT). In some cases, patients with stage IIIA-N2 NSCLC are considered operable, but the relative benefit of surgery is unclear. We report a post hoc, exploratory analysis of clinical outcomes in the PACIFIC trial, in patients with or without stage IIIA-N2 NSCLC.